ONCO

Onconetix is a $3.4M-market-cap commercial-stage biotech that no longer has a real commercial business. FY2025 revenue was just $815K and *fell 67.7%* year-over-year, and the MD&A confirms why: the company 'abandoned commercialization of ENTADFI' — an FDA-approved product it fully impaired at June 30, 2024 — and now stakes its entire future on Proclarix, a CE-marked EU prostate-diagnostic that it merely 'anticipates' selling in the U.S. as a lab-developed test through a LabCorp license. That is a hope, not a franchise: 'we do not have any products approved for sale' in the U.S., manufacturing is fully outsourced to 'single-source suppliers,' and the accumulated deficit is now -$131M against a company that has never earned a profit.

The balance sheet is a runway problem dressed up as stability. Yes, stockholders' equity is $15.8M and liabilities/equity is a benign 0.58x, but operating cash flow was -$9.68M in FY2025 against only $5.22M of cash — well under a single year of runway. Current liabilities ($9.14M) exceed current assets ($6.07M), so working capital is already negative. The MD&A explicitly flags 'the Company's cash runway and indebtedness' as the reason it killed ENTADFI, and states expenses 'will increase' as it tries to scale Proclarix. The only way this entity keeps operating is by raising capital — and the share count tells you how brutal that has been: shares outstanding collapsed 91.9% YoY to 3.58M (reverse-split math) while diluted EPS was -$16.56. Continued raises/reverse splits at a sub-$1 price are a near-certainty and will keep destroying per-share value.